What´s up at IZB
Dear Mister/Miss Titel ,
In recent months, we have reported on many new start-ups that we have been able to welcome to the IZB. Unfortunately, one company always has to leave us in return. At the end of March 2023, adivo GmbH has moved out of the IZB. However, we warmly congratulate the management for having to triple their space after only 5 years in order to continue their expansion. At the same time they started their first clinical trial. This brings adivo ever closer to their goal of developing cancer drugs for dogs and cats. The company is pushing into a billion-dollar market. A real ray of hope for all dog and cat lovers on this earth.
IZB also welcomed new management members at each of HTCR, INCYTON and Insempra. Glad you are now, or again, part of our network.
The Biotech Press Lounge at the IZB was again a very successful event in spring with more than 80 guests and many journalists. Dr. Daniel Reichert, LMU physician/Harvard Medical School presented the first atlas for human heart cells. Unbelievable how little was known about the heart until now. Dr. Nägler from Wellington Partners gave us a preview of therapies in 2043. Heimo Adamski from 4GENE presented his glycosylation: for example, this technology will produce a badge that starts to smell like smoke before a machine starts to burn. Never heard of it? Take a look at our press release.
Enjoy reading the many news from the IZB.
With best regards
Dr. Peter Hanns Zobel
Managing Director IZB